









Markets
/
Stocks
/
nasdaq-bvs
/

Bioventus Inc

BVS

9.241USD

+0.241+2.68%

Market hours （ET）Quotes delayed by 15 min

368.16MMarket Cap

27.08P/E TTM



Bioventus Inc

9.241

+0.241+2.68%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Bioventus Inc

Currency: USD Updated: 2026-03-24

Key Insights

Bioventus Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 3 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.75.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bioventus Inc's Score

Industry at a Glance

Industry Ranking

3 / 209

Overall Ranking

38 / 4547

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative-

Bioventus Inc Highlights

StrengthsRisks

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 26.82, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 49.87M shares, decreasing 0.00% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 19.50K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.49.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

14.750

Target Price

+70.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-24

The current financial score of Bioventus Inc is 7.86, ranking 55 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 157.90M, representing a year-over-year increase of 2.77%, while its net profit experienced a year-over-year increase of 9558.33%.

Score

Industry at a Glance

Previous score

7.86

Change



Financials

6.49

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.91

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.49

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.07

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.30

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Bioventus Inc's Company Valuation

Currency: USD Updated: 2026-03-24

The current valuation score of Bioventus Inc is 8.71, ranking 12 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 26.82, which is 765.70% below the recent high of 232.15 and 183.65% above the recent low of -22.43.

Score

Industry at a Glance

Previous score

8.71

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 3/209

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-24

The current earnings forecast score of Bioventus Inc is 8.50, ranking 26 out of 209 in the Healthcare Equipment & Supplies industry. The average price target is 15.00, with a high of 15.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

14.750

Target Price

+70.72%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

Bioventus Inc

BVS

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-24

The current price momentum score of Bioventus Inc is 9.10, ranking 10 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 9.75 and the support level at 8.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.86

Change

0.24

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(5)

Indicators

Value

Direction

MACD(12,26,9)

0.007

Buy

RSI(14)

59.326

Neutral

STOCH(KDJ)(9,3,3)

73.686

Buy

ATR(14)

0.439

Low Volatility

CCI(14)

121.211

Buy

Williams %R

26.761

Buy

TRIX(12,20)

0.245

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

8.942

Buy

MA10

8.869

Buy

MA20

8.802

Buy

MA50

8.401

Buy

MA100

7.899

Buy

MA200

7.383

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of Bioventus Inc is 10.00, ranking 1 out of 209 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 91.76%, representing a quarter-over-quarter decrease of 0.72%. The largest institutional shareholder is The Vanguard, holding a total of 2.94M shares, representing 4.36% of shares outstanding, with 13.67% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

EW Healthcare Partners

13.02M

Juniper Investment Company, LLC

6.94M

Smith & Nephew Group plc

6.23M

Nantahala Capital Management, LLC

5.81M

+10.03%

The Vanguard Group, Inc.

Star Investors

2.88M

+3.92%

BlackRock Institutional Trust Company, N.A.

2.81M

-0.22%

Royce Investment Partners

Star Investors

1.26M

+15.65%

Geode Capital Management, L.L.C.

1.10M

+4.36%

Kent Lake PR LLC

1.00M

+185.74%

State Street Investment Management (US)

876.43K

-0.87%

Risk Assessment

Currency: USD Updated: 2026-03-24

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bioventus Inc is 5.31, ranking 84 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.70. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Bioventus Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.